Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3316531 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy males~* Must be abstinent or use condoms with spermicide as well as 1 additional highly effective method of contraception or effective method of contraception during the study and for 5 months following dosing of study drug~* Must have a body mass index between 18 to 32.0 kilogram per meter square (kg/m²), inclusive, and a minimum body weight of 50 kilogram (kg)~* Must have suitable skin characteristics for the dermal capsaicin challenge and have demonstrated at least a 100 percent (%) increase in dermal flow following capsaicin challenge as part of the screening procedures and measured through laser Doppler imaging (LDI)~Exclusion Criteria:~* Must not have evidence of clinically significant active infection, fever of 100.5 degrees Fahrenheit (°F) (38 degrees Centigrade (°C)) or above, at baseline~* Must not show evidence of active or latent tuberculosis (TB)~* Must not have received live, attenuated live, or non-live vaccine(s) within 28 days of screening or intend to receive during the study~* Must not be immunocompromised~* Must not have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing~* Must not have significant allergies to humanised monoclonal antibodies~* Have a history of multiple or severe allergies or has had an anaphylactic reaction to prescription or nonprescription drugs or food~* Must not have had any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin~* Must not have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin that may interfere with the study assessments~* Must avoid excess tanning throughout the study and cannot cover forearms for 24 hours prior to each treatment period~* Must not have excessive hair growth on the volar surface of the forearm or currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis that cannot be discontinued for the duration of the study; participant must not have used any topical treatments within 7 days of the start of the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 300 mg LY3316531 Dose 1 (Type: EXPERIMENTAL): LY3316531 administered IV
- LY3316531 Dose 2 (Type: EXPERIMENTAL): The optional additional cohort (Dose 2) was not implemented as the data desired for treatment effect on dermal blood flow (DBF) was generated at the initial Dose 1 (300mg LY3316531)~LY3316531 administered IV
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).